Teclison Ltd.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.teclison.com
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Phase 2
Recruiting
- Conditions
- Colorectal Cancer; Lung Cancer
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT04701476
- Locations
- 🇺🇸
University of California, Irvine Medical Center, Orange, California, United States
🇨🇳China Medical University Hsinchu Hospital, Hsinchu, Taiwan
🇨🇳Chung Shan Medical University Hospital, Taichung, Taiwan
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Phase 2
Recruiting
- Conditions
- Hepatocellular CarcinomaGastric Cancer
- Interventions
- Combination Product: Trans-arterial tirapazamine embolization
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT03259867
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
TATE Versus TACE in Intermediate Stage HCC
Phase 2
Terminated
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03145558
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸Oregon Health Science University, Portland, Oregon, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Phase 1
Recruiting
- Conditions
- Hepatocellular CarcinomaGastrointestinal Cancer MetastaticNeuroendocrine Tumors
- Interventions
- Procedure: Conventional Transarterial Embolization (TAE)
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02174549
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States